were confident about the diagnosis, the latter was more likely to be accurate. Some discrepancies could result from premature sending of cases by referral pathologists. Indeed, in order to minimize the delays of patients' management some pathologists prefer to send cases to the expert center with a minimal set of techniques. This could in part explain why we did not observe a significant decline in the overall discordance rate over the fouryear period, in contrast to Proctor et al [2] . But we also believe that training in hematopathology has a long way to go before obtaining significant results. However, encouragingly, we observed that Lymphopath promoted the use of more specific antibody clones by referral pathologists as for example anti-cyclin D1/SP4 or anti-BCL2/SP66, thus improving the diagnostic rate of mantle cell lymphoma and follicular lymphoma respectively. Based on our study, we do not think that an expert review should be mandatory in all instances as illustrated by the weakest rate of discordance for cases sent with a formal diagnosis. Further investigations need to determine which level of skill (or training) should be reached and/or which ancillary facilities should be required to allow referral pathologists to select cases to send out for expert review.
Regarding the cost of the Lymphopath review, the government's funding is around 450 000 euros per year. Although this is a significant cost, we have to determine the financial impact of diagnostic changes in therapeutic management. Further economic evaluations are currently ongoing to investigate whether Lymphopath increases the cost effectiveness of patient's care.
Finally, since 2010 Lymphopath has provided a large national registry on all lymphoma subtypes in France (to date, over 60 000 lymphomas) which could be useful for large epidemiological studies. For example, Lymphopath has shown that angioimmunoblastic lymphoma is the most frequent T-cell lymphomas in France [5] . It also gives the opportunity to identify the frequency of uncommon entities such as plasmablastic lymphoma [6] or the emergence of new provisional entities such as anaplastic large cells lymphoma associated with breast implants [7] .
To conclude, our study implies that in around 20% of cases, lymphoma diagnoses are better determined in collaboration with expert pathologists. Based on the upcoming 2016 WHO classification which identifies an increasing number of lymphoma subtypes, it will be even more important to assess accurate diagnoses in the near future especially in the current age of personalized medicine.
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